Found 8 matching trials
An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa PHASE3 The purpose of this study is to conduct long-term surveillance for efficacy...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa PHASE3 The purpose of this observer-blind study is to gather key efficacy, safety,...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults PHASE2 This study will evaluate whether administration of two investigational mala...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen PHASE2 This study is being done to assess the possibility of the potential integra...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults PHASE2 This study is designed to evaluate safety, reactogenicity, immunogenicity, ...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants PHASE2 The aim of the malaria vaccine program of the MVI/GSK partnership is to dev...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children PHASE3 The purpose of this study is to show the consistency of different lots of a...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine PHASE2 The RTS,S/AS02A vaccine (or GSK 257049 vaccine), GSK Biologicals' candidate...
Show More Location
GSK Investigational Site
Learn More & Join Trial